Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Imab source : Www.biospace.com save search
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
Published: 2023-11-01 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -4.9%
H: 13.24%
C: 12.5%
antibody
Embattled Researchers See Path Forward for Anti-CD47 Cancer Drugs
Published: 2023-10-30 (Crawled : 05:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 3.28%
H: 5.56%
C: 2.38%
cd47 cancer
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.0%
H: 2.24%
C: -2.99%
HI-Bio to Present at the American Society of Nephrology Kidney Week 2023 Annual Meeting
Published: 2023-10-13 (Crawled : 22:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -1.49%
H: 5.68%
C: 1.52%
kidney meeting week
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -0.71%
H: 8.57%
C: 7.14%
abl503 antibody
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
Published: 2023-09-27 (Crawled : 15:30) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -2.38%
axes trial
AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline
Published: 2023-09-27 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -2.38%
abbvie contract cancer pipeline car-t
AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.83%
H: 5.79%
C: 5.79%
cd47 abbvie antibody deal
AbbVie Ends I-Mab Partnership for CD47 Antibody Compounds, Products
Published: 2023-09-25 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.83%
H: 5.79%
C: 5.79%
cd47 partnership abbvie antibody
I-Mab Announces Upcoming Participation at September Conferences - September 5, 2023
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.0%
H: 6.19%
C: -7.73%
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
Published: 2023-08-24 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.57%
europe patent international
ALX Oncology Axes Two CD47 Programs on Disappointing Results
Published: 2023-08-11 (Crawled : 23:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -1.57%
H: 3.39%
C: 1.2%
cd47 axes results
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -1.16%
H: 0.0%
C: -1.96%
report business financial
HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases
Published: 2023-07-11 (Crawled : 18:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.36%
H: 3.25%
C: 0.0%
hib210 study
I-Mab Announces the Appointment of Raj Kannan as CEO
Published: 2023-06-22 (Crawled : 14:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.0%
H: 0.98%
C: -2.22%
ceo
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy
Published: 2023-05-25 (Crawled : 15:20) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.97%
fda nephropathy drug treatment designation
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
Published: 2023-04-24 (Crawled : 18:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -1.49%
H: 1.51%
C: -3.64%
cd47 antibody china study
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
Published: 2023-03-08 (Crawled : 01:00) - biospace.com/
TCON | $1.97 -6.64% -7.11% 240K
|
Health Technology
|
| O: -3.33%
H: 4.13%
C: -4.83%
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -1.24%
H: 2.51%
C: -0.25%
pharmaceuticals financial update results
Astellas Scores Second CLDN18.2-Positive Gastric Cancer Win
Published: 2022-12-16 (Crawled : 15:20) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -3.48%
H: 2.77%
C: 0.28%
cldn18 cancer
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
Published: 2022-12-14 (Crawled : 18:00) - biospace.com/
TCON | $1.97 -6.64% -7.11% 240K
|
Health Technology
|
| O: 14.5%
H: 7.33%
C: -14.0%
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: -2.89%
H: 6.5%
C: 4.07%
ongoing pharmaceuticals trial response positive results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
JOE 4 | $54.88 1.22% 0.22% 210K
|
Finance
JBI 4 | $15.14 1.34% 0.0% 2.9M
|
Your saved searches
Save your searches and get alerts when important news are released.